Furthermore, IGFBP-3 has been reported to exert IGF-independent tumor-suppressive effects by interacting with cell surface receptors such as transmembrane protein 219 and modulating key apoptotic pathways, including tumor protein p53 and transforming growth factor-beta signaling cascades. Here, CD177 is linked to neoplasm.